NCT02436759View on ClinicalTrials.gov

Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

PHASE3CompletedINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions

Acquired Blepharoptosis

Interventions

DRUG

RVL-1201

RVL-1201 Ophthalmic Solution 0.1%

DRUG

RVL-1201 Vehicle Placebo

Trial Locations (14)

18704

Kingston

30076

Roswell

33324

Plantation

33773

Largo

33901

Fort Myers

34239

Sarasota

37215

Nashville

45040

Mason

66204

Shawnee Mission

66762

Pittsburg

90701

Artesia

92663

Newport Beach

93454

Santa Maria

95670

Rancho Cordova

All Listed Sponsors

lead

RVL Pharmaceuticals, Inc.

INDUSTRY

NCT02436759 - Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis | Biotech Hunter | Biotech Hunter